

# Metoperil XL 50

**Brand Name:** Metoperil XL 50 Tablet

**Dosage Form:** Extended Release Tablet

**Therapeutic Category:** Beta-Blocker / Antihypertensive

**Composition:**

Each uncoated extended-release tablet contains:

- **Metoprolol Succinate I.P.** – 50 mg (as extended release)
- **Excipients** – q.s.

**Description:**

Metoperil XL 50 Tablet contains **Metoprolol Succinate**, a cardioselective  $\beta_1$ -adrenergic receptor blocker formulated in extended-release form for once-daily dosing. It helps in lowering blood pressure, managing angina, and improving survival after myocardial infarction.

**Indications:**

- Hypertension
- Angina pectoris
- Heart failure (chronic, stable, symptomatic)
- Secondary prevention post-myocardial infarction

**Pharmacological Action:**

Metoprolol acts selectively on  $\beta_1$  receptors, reducing cardiac output, heart rate, and myocardial contractility. It improves exercise tolerance and lowers myocardial oxygen demand without significant  $\beta_2$  (bronchial) receptor activity at therapeutic doses.

**Dosage and Administration:**

As prescribed by the physician.

Recommended once-daily oral dose in hypertension: 25–100 mg/day.

Swallow whole; do not crush or chew.

**Contraindications:**

- Known hypersensitivity to Metoprolol
- Severe bradycardia, heart block > first degree
- Decompensated heart failure
- Cardiogenic shock

**Precautions and Warnings:**

- Caution in diabetes, asthma, and peripheral vascular diseases
- Gradual dose reduction required before discontinuation
- May mask symptoms of hypoglycemia

**Adverse Effects:**

- Fatigue, dizziness
- Bradycardia, hypotension
- Gastrointestinal discomfort
- Cold extremities

**Storage:**

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight.

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for